openPR Logo
Press release

In Depth Research on Global Diabetes Drug Market & Pipeline Insight 2015

10-04-2017 08:05 AM CET | Health & Medicine

Press release from: Kuick Resarch

In Depth Research on Global Diabetes Drug Market & Pipeline

"Global Diabetes Drug Market & Pipeline Insight 2015" Report Highlight:

* Global Diabetes Drug Market Overview
* Global Diabetic Drug Clinical Pipeline by Company & Phase
* Global Diabetic Drug Clinical Pipeline: 817 Drugs
* Majority in Preclinical Phase: 205 Drugs
* Type 2 Diabetes Mellitus Drugs in Pipeline: 380 Drugs
* Type 1 Diabetes Mellitus Drugs in Pipeline: 79 Drugs
* Diabetic Nephropathies Drugs in Pipeline: 41 Drugs
* Marketed Diabetic Drugs: 99 Drugs

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report-Global-Diabetes-Drug-Market-&-Pipeline-Insight-2015.php

Table of Contents

1. Introduction to Diabetes

2. Diabetes Drug Mechanism

3. Global Diabetes Drug Market Overview
3.1 Current Market Scenario
3.2 Global Diabetes Drug Pipeline Overview

4. Global Diabetes Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Development & Commercialization Challenges

5. Global Diabetes Drug Market Future Prospects

6. Diabetic Neuropathies Drug Clinical Pipeline by Company & Phase
6.1 Research to till Registered
6.2 Marketed Drug Clinical Insight

7. Diabetic Nephropathies Drug Clinical Pipeline by Company & Phase
7.1 Research to till Registered
7.2 Marketed Drug Clinical Insight

8. Diabetes Mellitus Drug Clinical Pipeline by Company & Phase
8.1 Phase Research to till Registered
8.2 Marketed Drug Clinical Insight

9. Type 1 Diabetes Mellitus Drug Clinical Pipeline by Company & Phase
9.1 Research to till Registered
9.2 Marketed Drug Clinical Insight

10. Type 2 Diabetes Mellitus Drug Clinical Pipeline by Company & Phase
10.1 Research to till Registered
10.2 Marketed Drug Clinical Insight

11. Diabetic Foot Ulcer Drug Clinical Pipeline by Company & Phase
11.1 Research to till Phase-III
11.2 Marketed Drug Clinical Insight

12. Diabetic Macular Oedema Drug Clinical Pipeline by Company & Phase
12.1 Research to till Registered
12.2 Marketed Drug Clinical Insight

13. Diabetic Gastroparesis Drug Clinical Pipeline by Company & Phase
13.1 Preclinical to till Phase-III
13.2 Marketed Drug Clinical Insight

14. Diabetic Retinopathy Drug Clinical Pipeline by Company & Phase
14.1 Research to till Phase-III

15. Prediabetic State Drug Clinical Pipeline by Company & Phase
15.1 Phase-II

16. Diabetes Drug Clinical Pipeline by Company & Phase
16.1 Research to till Registered
16.2 Marketed Drug Clinical Insight

17. Competitive Landscape
17.1 AstraZeneca
17.2 Boehringer Ingelheim
17.3 Eli Lily
17.4 GalaxoSmithKline
17.5 Johnson & Johnson
17.6 MannKind Corporation
17.7 Merck
17.8 Novartis
17.9 Pfizer
17.10 Sanofi

Figure 1-1: Types of Diabetes
Figure 1-2: Diseases Associated with Diabetes
Figure 1-3: Diabetes Causing Factors
Figure 2-1: Function of Insulin
Figure 2-2: Mechanism of Metformin
Figure 2-3: Mechanism of Pramlintide
Figure 2-4: Mechanism of Sulphonylureas
Figure 2-5:Mechanism of Alpha-Glycosidase Inhibitors
Figure 2-6:Mechanism of Thiazolidinediones
Figure 3-1: Global Diabetes Incidences (Million), 2014 & 2035
Figure 3-2:Global Distribution of Diabetes Patients (Million), 2014
Figure 3-3: Diabetec Neuropathies Pipeline by Phase(%), 2015
Figure 3-4: Diabetec Neuropathies Pipeline by Phase(Number), 2015
Figure 3-5: Diabetic Nephropathies Pipeline by Phase(%), 2015
Figure 3-6: Diabetic Nephropathies Pipeline by Phase(Number), 2015
Figure 3-7: Diabetes Mellitus Pipeline by Phase(%), 2015
Figure 3-8: Diabetes Mellitus Pipeline by Phase(Number), 2015
Figure 3-9: Type 1 Diabetes Mellitus Pipeline by Phase(%), 2015
Figure 3-10: Type 1 Diabetes Mellitus Pipeline by Phase(Number), 2015
Figure 3-11: Type 2 Diabetes Mellitus Pipeline by Phase(%), 2015
Figure 3-12: Type 2 Diabetes Mellitus Pipeline by Phase(Number), 2015
Figure 3-13: Diabetic Foot Ulcer Pipeline by Phase(%), 2015
Figure 3-14: Diabetic Foot Ulcer Pipeline by Phase(Number), 2015
Figure 3-15: Diabetic Macular Oedema Pipeline by Phase(%), 2015
Figure 3-16: Diabetic Macular Oedema Pipeline by Phase(Number), 2015
Figure 3-17: Diabetic Gastroparesis Pipeline by Phase(%), 2015
Figure 3-18: Diabetic Gastroparesis Pipeline by Phase(Number), 2015
Figure 3-19: Diabetic Retinopathy Pipeline by Phase(%), 2015
Figure 3-20: Diabetic Retinopathy Pipeline by Phase(Number), 2015
Figure 3-21: Diabetes Insipidus Pipeline by Phase(%), 2015
Figure 3-22: Diabetes Insipidus Pipeline by Phase(Number), 2015
Figure 3-23: Multiple Diabetic Pipeline by Phase(%), 2015
Figure 3-24: Multiple Diabetic Pipeline by Phase(Number), 2015
Figure 4-1: Global Diabetes Drug Market Favorable Parameters

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release In Depth Research on Global Diabetes Drug Market & Pipeline Insight 2015 here

News-ID: 753678 • Views:

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Drug

Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June. The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug